Mostajeran Kathy, Boswell Hillary, Haidar Ziad
Gulf Coast Educational Consortium/HCA Houston Healthcare West, 12141 Richmond Ave. Houston, TX 77082, USA.
Case Rep Obstet Gynecol. 2021 Jun 29;2021:5553296. doi: 10.1155/2021/5553296. eCollection 2021.
Venous thromboembolic events (VTE), specifically pulmonary embolisms, account for a significant portion of maternal morbidity and mortality. Due to the procoagulant physiological changes that occur, pregnancy and the postpartum period are known risk factors for thromboembolic events. The risk is greatest during the first-week postpartum and remains elevated for up to six weeks as compared to the general population. Treatment guidelines regarding the use of thrombolytics for massive pulmonary embolism occurring in pregnancy and the postpartum are not well established. In nonpregnant populations, thrombolytic agents are well known to decrease the mortality in the setting of a massive pulmonary embolism. However, in the absence of management guidelines, thrombolysis in pregnancy remains guided by case reports and case series. We present a case of a massive pulmonary embolism (PE) causing hemodynamic instability during the postpartum period treated with tissue plasminogen activator (tPA). The case was complicated by delayed postpartum hemorrhage successfully managed with the uterotonic methylergometrine. The patient was started on oral anticoagulation and continued for six months without recurrent VTE. Our case demonstrates a rare occurrence of a saddle embolism after a vaginal delivery within the first postpartum week which was successfully managed with the use of systemic thrombolysis and minimal intervention to manage the iatrogenic delayed postpartum hemorrhage. To the authors' knowledge, no other similar case report exists. This case highlights the need to develop guidelines for the use of thrombolysis in mothers who present with massive pulmonary embolus and a noninvasive means to manage adverse bleeding events in the puerperium.
静脉血栓栓塞事件(VTE),特别是肺栓塞,在孕产妇发病和死亡中占很大比例。由于孕期发生的促凝生理变化,妊娠和产后时期是已知的血栓栓塞事件风险因素。与普通人群相比,产后第一周风险最高,且在长达六周的时间内风险持续升高。关于在妊娠和产后发生的大面积肺栓塞使用溶栓药物的治疗指南尚未明确确立。在非妊娠人群中,众所周知溶栓药物可降低大面积肺栓塞患者的死亡率。然而,由于缺乏管理指南,孕期溶栓治疗仍以病例报告和病例系列为指导。我们报告一例产后发生大面积肺栓塞(PE)导致血流动力学不稳定,使用组织纤溶酶原激活剂(tPA)治疗的病例。该病例并发产后延迟出血,使用宫缩剂甲基麦角新碱成功处理。患者开始口服抗凝治疗并持续六个月,未再发生VTE。我们的病例显示产后第一周内阴道分娩后罕见地发生鞍状栓塞,通过全身溶栓及最小化干预处理医源性产后延迟出血成功治疗。据作者所知,尚无其他类似病例报告。该病例凸显了为出现大面积肺栓塞的母亲制定溶栓治疗指南以及采用非侵入性方法处理产褥期不良出血事件的必要性。